All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1500+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Merus’ Bizengri (targeting HER2, HER3) nabs FDA approval in lung cancer and pancreatic adenocarcinoma
Monoclonal antibody, lung cancer, pancreatic adenocarcinoma - Read more

AstraZeneca’s Imfinzi (targeting CD274) nabs FDA label expansion in lung cancer
Monoclonal antibody, lung cancer - Read more

Immunocore’s Kimmtrak (targeting HLA-A*02:01) bispecific lands UK NICE recommendation in uveal melanoma
Bispecific T cell engager, uveal melanoma, cancer - Read more

LEO Pharma lands UK MHRA marketing authorization for Anzupgo (pan-JAK inhibitor) in chronic hand eczema
Small molecule, chronic hand eczema - Read more

Simcere Pharmaceutical’s Sanbexin lands marketing approval in stroke from Chinese NMPA
Small molecule, stroke - Read more

THE GOOD
Business Development

GSK buys option to ex-China license for Duality Biologics’ DB-1324 (undisclosed gastrointestinal cancer target) ADC
Antibody-drug conjugate, gastrointestinal cancer - Read more

Partner Therapeutics buys US commercial rights for Zeno (targeting HER2, HER3) from Merus
Bispecific antibody, lung cancer, pancreatic cancer - Read more

Martin Pharmaceuticals buys Ciquaaz (dopamine prodrug) ex-Japan, ex-China rights in chronic liver disease from Mitsubishi Tanabe Pharma
Small molecule, liver disease - Read more

Theratechnologies buys Canada commercial rights to Ionis Pharmaceuticals’ olezarsen (apoC-III inhibitor) and donidalorsen (targeting prekallikrein)
Antisense oligonucleotide, amilial chylomicronemia syndrome, severe hypertriglyceridemia, hereditary angioedema - Read more

Genmab buys development and commercial rights for another Scancell anti-glycan antibody
Monoclonal antibody, cancer - Read more

ADVANZ Pharma buys ex-Japan, ex-China rights to Progynova & Cyclo-Progynova (hormone replacement) from Bayer
Small molecule, estrogen deficiency, post-menopausal osteoporosis, menstrual regulator - Read more 

Novo Nordisk buys Czech Republic-based manufacturing site from Novavax
Manufacturing site - Read more

PRESENTED BY YOU?
Get the attention of 1500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Eli Lilly’s Zepbound outperforms Novo Nordisk’s Wegovy in head-to-head obesity trial
GLP-1, obesity - Read more

VisaVision Biotech posts positive topline Ph2 data for VVN461 (JAK1/TYK2 immunomodulator) in post-cataract surgery inflammation
Small molecule, post-operative inflammation following cataract surgery - Read more

Atea Pharmaceuticals’ bemnifosbuvir and ruzasvir combo succeeds in hepatitis C Ph2 trial
Small molecule, hepatitis C infection - Read more

ImPact Biotech showcases updated Ph3 data for padeliporfin vascular targeted photodynamic therapy in urothelial cancer
Small molecule, urothelial cancer, photodynamic therapy - Read more

Akeso touts initial positive Ph1b/2 data for cadonilimab (targeting PD-1/CTLA-4) in lung cancer
Bispecific antibody, lung cancer - Read more

Teva Pharmaceutical showcases positive Ph3 data for Ajovy (targeting CGRP) in episodic migraine prevention in children and adolescents
Monoclonal antibody, episodic migraine - Read more

Everest Medicine touts “promising” Ph1b/2a data for EVER001 (Bruton’s tyrosine kinase inhibitor) in primary membranous nephropathy
Small molecule, primary membranous nephropathy - Read more

THE GOOD
Fundraises

BioRock Ventures aims for $60M for second fund
Biotech investing, venture capital - Read more

Antag Therapeutics €80M ($84M) Series A, fuelling a novel approach to weight loss
Peptide, obesity - Read more

TRIO Pharmaceuticals $3.1M equity financing, bispecifics for cancer
Bispecific antibody, cancer - Read more

Refoxy Pharmaceuticals €9.1M ($9.6M) Seed extension, small molecules for age-related diseases
Small molecule, age-related diseases, idiopathic pulmonary fibrosis - Read more

Serina Therapeutics $10M stock sale, “drug optimization” platform for neurological disease
Small molecule, Parkinson’s disease, platform - Read more

Janux Therapeutics $350M public offering
Trispecific antibody, prostate cancer - Read more

Foresee Pharmaceuticals $42.1M public offering
Polypeptide, cancer, autoimmune - Read more

miDiagnostics €30M ($31.6M) Series D, miniaturized qPCR testing
qPCR, diagnostics, quality control, release test - Read more 

THE GOOD
Investments

Novo Nordisk invests $409M in new quality control facility in Hillerød, Denmark
New facility, quality control - Read more

THE GOOD
Partnerships

Eli Lilly, Rondo Therapeutics CD28 bispecific antibody research and licensing collab
Bispecific antibody, cancer, T cell-engaging - Read more

GSK, Rgenta Therapeutics RNA-targeting small molecule discovery collab
Small molecule, cancer, neurological disorder, drug discovery - Read more

Dewpoint Therapeutics, Mitsubishi Tanabe Pharma research collaboration to advance TDP-43 (condensate modulator) in ALS
Small molecule, amyotrophic lateral sclerosis - Read more

Lisata Therapeutics, Kuva Labs magnetic resonance imaging agent collab and licensing agreement
Cyclic peptide, magnetic resonance imaging, imaging agent, solid tumor, cancer - Read more

THE GOOD
Patient Access

Vertex Pharmaceuticals, bluebird bio agree to outcome-based payment models for their sickle cell disease gene therapies with the US’s Centers for Medicare & Medicaid Services
Gene therapy, sickle cell disease, Medicare, Medicaid - Read more

THE GOOD
Politics & Policy

Moderna works to justify pandemic preparation efforts to critics from incoming Trump administration
Pandemic preparedness, vaccine - Read more [Paywall]

THE GOOD
Research

Arrakis Therapeutics’ touts promising mouse study results for RNA-targeting small molecule in myotonic dystrophy type 1
Small molecule, myotonic dystrophy type 1 - Read more

Leptin, a long abandoned obesity hopeful, might find renewed life as an investigational molecule produced more weight-loss in mice when activating both leptin and GLP-1 receptors
Peptide, obesity, weight loss - Read more [Paywall]

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Relmada Therapeutics’ REL-1017 (NMDA receptor channel blocker) likely to come up short in Ph3 trial
Small molecule, major depressive disorder - Read more

THE UGLY
Criminal Acts

UnitedHealthcare CEO slain in what looks to be a targeted shooting in NYC, prior to UnitedHealth investor conference
Health insurance, shooting - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here